Lung Cancer Trial, Recruiting NCT06410300 Sponsor: Bo Lu Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT06410300
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are older than 18 years of age
  • People who have been diagnosed with locally advanced lung cancer (either non-small cell or small cell type) and have a treatment plan that includes high-dose radiation therapy (45Gy or more) followed by immunotherapy
  • People who are not receiving chemotherapy and radiation therapy at the same time are eligible to join
  • People already taking part in another clinical trial that involves chest radiation and immunotherapy may also be eligible to join this trial at the same time
  • People with a general health status rated as reasonably functional (rated 0–2 on a standard medical scale, meaning able to carry out at least some daily activities) (confirm with trial site)
  • People with a life expectancy of at least 6 months
  • People who are able to read and sign a consent form before the study begins

Who may not be able to join:

  • People who have previously had radiation therapy to the chest area
  • People whose treating doctor has determined they are not suitable candidates for curative chest radiation therapy or immunotherapy
  • People with other serious ongoing or sudden physical or mental health conditions that, in the opinion of the research team, could make participation unsafe or unsuitable

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Bo Lu, MD, Chair, Department of Radiation Oncology

Phone: 318-816-3582

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Bo Lu
Registry
ClinicalTrials.gov
Start date
19 April 2024
Est. completion
19 April 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Clinical cardiopulmonary toxicities

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov